{
    "root": "d1387fa9-4df4-4485-ab77-f756daa18b95",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Liothyronine Sodium",
    "value": "20250520",
    "ingredients": [
        {
            "name": "LIOTHYRONINE SODIUM",
            "code": "GCA9VV7D2N"
        }
    ],
    "indications": "Liothyronine sodium is an L-triiodothyronine (T3) indicated for: • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) • Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) • Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 ) Limitations of Use : - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. ( 1 ) - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. ( 1 )",
    "contraindications": "• Administer liothyronine sodium orally once daily and individual dosage according to patient response and laboratory findings ( 2.1 ) • See full prescribing information for recommended dosage for hypothyroidism ( 2.2 ) TSH suppression in well-differentiated thyroid cancer ( 2.3 ) and for thyroid suppression test ( 2.4 ) • When switching a patient to liothyronine sodium, discontinue levothyroxine therapy and initiate liothyronine sodium at a low dosage. Gradually increase the dose according to the patient's response ( 2.5 ) • Adequacy of therapy determined with periodic monitoring of TSH and T3 levels as well as clinical status ( 2.6 )",
    "warningsAndPrecautions": "Liothyronine sodium tablets (round, white to off-white) are supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              Strength\n                           \n                           \n                              Tablet Markings\n                           \n                           \n                              NDC – bottles of 100\n                           \n                        \n                     \n                     \n                        \n                           \n                              5 mcg\n                           \n                           \n                              Debossed with KPI on one side and 115 on the other side\n                           \n                           \n                              59762-1206-1\n                           \n                        \n                        \n                           \n                              25 mcg\n                           \n                           \n                              Scored on one side and debossed with KPI and 116 on the other side\n                           \n                           \n                              59762-1207-1\n                           \n                        \n                        \n                           \n                              50 mcg\n                           \n                           \n                              Scored on one side and debossed with KPI and 117 on the other side\n                           \n                           \n                              59762-1208-1",
    "adverseReactions": "Liothyronine sodium is contraindicated in patients with uncorrected adrenal insufficiency [see \n                     \n                     \n                        Warnings and Precautions (5.3)\n                        ]\n                     \n                     ."
}